



Clinical trial results:

A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176/GSK3532795, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults

Summary

EudraCT number	2013-005487-26
Trial protocol	DE ES GB IT
Global end of trial date	21 August 2017

Results information

Result version number	v2 (current)
This version publication date	02 September 2018
First version publication date	09 August 2017
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	205891
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	ViiV Healthcare
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 July 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	21 August 2017
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate antiviral efficacy of 3 doses (60, 120 and 180 mg) of BMS-955176/GSK3532795, and EFV, each when given in combination with TDF/FTC in treatment-naïve subjects by determining the proportion of treatment-naïve subjects with plasma HIV-1 RNA < 40 c/mL at Week 24

Protection of trial subjects:

NA

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 May 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 41
Country: Number of subjects enrolled	Canada: 24
Country: Number of subjects enrolled	Chile: 20
Country: Number of subjects enrolled	France: 11
Country: Number of subjects enrolled	Germany: 23
Country: Number of subjects enrolled	Italy: 17
Country: Number of subjects enrolled	Mexico: 40
Country: Number of subjects enrolled	Poland: 15
Country: Number of subjects enrolled	Puerto Rico: 7
Country: Number of subjects enrolled	South Africa: 45
Country: Number of subjects enrolled	Spain: 20
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	United States: 38
Worldwide total number of subjects	305
EEA total number of subjects	90

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	302
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was originally designed for 96 weeks of treatment in treatment naïve human immunodeficiency virus-1 (HIV-1) infected adults; however, it was terminated early due to gastrointestinal intolerability and treatment emergent resistance. The study was conducted at 58 centers in 12 countries.

Pre-assignment

Screening details:

A total of 305 participants were screened, of which 210 were randomized to 1 of 4 treatment arms. Of 210 participants, only 206 received study treatment. Four participants were randomized but not treated as: 2 participants were randomized in error, 1 participant was lost to follow-up and 1 participant withdrew consent.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	BMS-955176/GSK3532795 60 mg + TDF/FTC

Arm description:

Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label tenofovir/emtricitabine (TDF/FTC) 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg at bed time on an empty stomach, without food from Day 1 to Week 96.

Arm type	Experimental
Investigational medicinal product name	BMS-955176/GSK3532795 60mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 60 mg active dose.

Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 120 mg.

Investigational medicinal product name	Placebo to match EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Arm title	BMS-955176/GSK3532795 120 mg + TDF/FTC
------------------	----------------------------------------

Arm description:

Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing EFV placebo matching 600 mg at bed time on an empty stomach, without food, from Day 1 to Week 96.

Arm type	Experimental
Investigational medicinal product name	BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 120 mg active dose.

Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 60 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 60 mg.

Investigational medicinal product name	Placebo to match EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Arm title	BMS-955176/GSK3532795 180 mg + TDF/FTC
------------------	----------------------------------------

Arm description:

Participants took one pill once daily from each of the three blinded bottles provided to them, containing

BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing EFV placebo matching 600 mg once daily at bed time on an empty stomach, without food from Day 1 to Week 96.

Arm type	Experimental
Investigational medicinal product name	BMS-955176/GSK3532795 60mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 60 mg active dose.

Investigational medicinal product name	Placebo to match EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Investigational medicinal product name	BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 120 mg active dose.

Arm title	EFV 600 mg + TDF/FTC
------------------	----------------------

Arm description:

Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill containing EFV 600 mg active dose once daily at bed time on an empty stomach, without food from Day 1 to Week 96.

Arm type	Experimental
Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 60 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 60 mg.

Investigational medicinal product name	EFV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg.

Investigational medicinal product name	TDF/FTC 300 mg/ 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing open-label TDF/FTC 300 mg/ 200 mg.

Investigational medicinal product name	Placebo to match BMS-955176/GSK3532795 120 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

In the morning, with a meal, participants took one pill once daily from the bottle containing BMS-955176/GSK3532795 placebo matching 120 mg.

Number of subjects in period 1^[1]	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC
Started	50	52	51
Completed	0	0	0
Not completed	50	52	51
Consent withdrawn by subject	4	-	1
Subject reached protocol-defined stopping criteria	-	1	1
Adverse event, non-fatal	1	3	5
Unknown	-	1	1
Poor/Non-compliance	1	-	1
Lost to follow-up	1	3	1
Lack of efficacy	4	4	-
Administrative reason by sponsor	39	40	41

Number of subjects in period 1^[1]	EFV 600 mg + TDF/FTC
Started	53
Completed	0
Not completed	53
Consent withdrawn by subject	3

Subject reached protocol-defined stopping criteria	-
Adverse event, non-fatal	10
Unknown	-
Poor/Non-compliance	-
Lost to follow-up	1
Lack of efficacy	-
Administrative reason by sponsor	39

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 305 participants were enrolled, of which 210 were randomized and only 206 received randomized treatment.

Baseline characteristics

Reporting groups

Reporting group title	BMS-955176/GSK3532795 60 mg + TDF/FTC
Reporting group description:	
Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label tenofovir/emtricitabine (TDF/FTC) 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg at bed time on an empty stomach, without food from Day 1 to Week 96.	
Reporting group title	BMS-955176/GSK3532795 120 mg + TDF/FTC
Reporting group description:	
Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing EFV placebo matching 600 mg at bed time on an empty stomach, without food, from Day 1 to Week 96.	
Reporting group title	BMS-955176/GSK3532795 180 mg + TDF/FTC
Reporting group description:	
Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing EFV placebo matching 600 mg once daily at bed time on an empty stomach, without food from Day 1 to Week 96.	
Reporting group title	EFV 600 mg + TDF/FTC
Reporting group description:	
Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill containing EFV 600 mg active dose once daily at bed time on an empty stomach, without food from Day 1 to Week 96.	

Reporting group values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC
Number of subjects	50	52	51
Age categorical Units: Subjects			
Age continuous			
Baseline characteristics is presented for Treated Subjects Population, also known as the modified intent-to-treat (mITT) Population which comprised of all participants who received at least one dose of BMS-955176 or EFV.			
Units: years			
arithmetic mean	31.8	34.7	35.5
standard deviation	± 8.26	± 11.29	± 11.34
Gender categorical Units:			
Male	42	44	44
Female	8	8	7
Race/Ethnicity, Customized Units: Subjects			
White	39	38	41

Black or African American	8	10	6
American Indian or Alaska Native	0	0	1
Unknown	3	4	3

Reporting group values	EFV 600 mg + TDF/FTC	Total	
Number of subjects	53	206	
Age categorical			
Units: Subjects			

Age continuous			
Baseline characteristics is presented for Treated Subjects Population, also known as the modified intent-to-treat (mITT) Population which comprised of all participants who received at least one dose of BMS-955176 or EFV.			
Units: years			
arithmetic mean	32.9		
standard deviation	± 9.35	-	
Gender categorical			
Units:			
Male	46	176	
Female	7	30	
Race/Ethnicity, Customized			
Units: Subjects			
White	40	158	
Black or African American	9	33	
American Indian or Alaska Native	0	1	
Unknown	4	14	

End points

End points reporting groups

Reporting group title	BMS-955176/GSK3532795 60 mg + TDF/FTC
Reporting group description: Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label tenofovir/emtricitabine (TDF/FTC) 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg at bed time on an empty stomach, without food from Day 1 to Week 96.	
Reporting group title	BMS-955176/GSK3532795 120 mg + TDF/FTC
Reporting group description: Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing EFV placebo matching 600 mg at bed time on an empty stomach, without food, from Day 1 to Week 96.	
Reporting group title	BMS-955176/GSK3532795 180 mg + TDF/FTC
Reporting group description: Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill once daily from the bottle containing EFV placebo matching 600 mg once daily at bed time on an empty stomach, without food from Day 1 to Week 96.	
Reporting group title	EFV 600 mg + TDF/FTC
Reporting group description: Participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 96. The doses were administered in the morning with a meal. Participants took one pill containing EFV 600 mg active dose once daily at bed time on an empty stomach, without food from Day 1 to Week 96.	

Primary: Number of participants with plasma HIV-1 ribonucleic acid (RNA) <40 copies per milliliter (c/mL) at Week 24 using Food and Drug Administration (FDA) snapshot algorithm

End point title	Number of participants with plasma HIV-1 ribonucleic acid (RNA) <40 copies per milliliter (c/mL) at Week 24 using Food and Drug Administration (FDA) snapshot algorithm ^[1]
End point description: Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV 1 RNA <40 c/mL at Week 24 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window (18 to 30 weeks) to determine response. Analysis was performed on mITT Population, which comprised of randomized participants who received at least 1 dose of BMS-955176/GSK3532795 or EFV.	
End point type	Primary
End point timeframe: Week 24	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis were performed.	

End point values	BMS- 955176/GSK35 32795 60 mg + TDF/FTC	BMS- 955176/GSK35 32795 120 mg + TDF/FTC	BMS- 955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[2]	52 ^[3]	51 ^[4]	53 ^[5]
Units: Participants	38	43	42	41

Notes:

[2] - mITT Population

[3] - mITT Population

[4] - mITT Population

[5] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA < 40 c/mL at Weeks 48 and 96 using FDA snapshot algorithm

End point title	Number of participants with plasma HIV-1 RNA < 40 c/mL at Weeks 48 and 96 using FDA snapshot algorithm
-----------------	--------------------------------------------------------------------------------------------------------

End point description:

Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV 1 RNA <40 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. The analysis was performed using mITT Population (observed), which consisted of participants in the mITT Population excluding participants who had no HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). 99999 indicates data was not collected for Week 96 analysis; as the study was terminated early. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 48 and 96

End point values	BMS- 955176/GSK35 32795 60 mg + TDF/FTC	BMS- 955176/GSK35 32795 120 mg + TDF/FTC	BMS- 955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[6]	52 ^[7]	51 ^[8]	53 ^[9]
Units: Participants				
Week 48; n=40, 42, 40, 43	35	41	40	40
Week 96; n=0, 0, 0, 0	99999	99999	99999	99999

Notes:

[6] - mITT Population (observed)

[7] - mITT Population (observed)

[8] - mITT Population (observed)

[9] - mITT Population (observed)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA < 200 c/mL at Week 24 using FDA snapshot algorithm

End point title	Number of participants with plasma HIV-1 RNA < 200 c/mL at Week 24 using FDA snapshot algorithm
End point description: Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV-1 RNA <200 c/mL at Week 24 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response.	
End point type	Secondary
End point timeframe: Week 24	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[10]	52 ^[11]	51 ^[12]	53 ^[13]
Units: Participants				
Week 24; n=50, 52, 51, 53	40	44	43	44

Notes:

[10] - mITT Population

[11] - mITT Population

[12] - mITT Population

[13] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with plasma HIV-1 RNA < 200 c/mL at Weeks 48 and 96

End point title	Number of participants with plasma HIV-1 RNA < 200 c/mL at Weeks 48 and 96
End point description: Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. The antiviral efficacy was determined by the number of participants with plasma HIV-1 RNA <200 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm. This used the last on-treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. The analysis was performed using mITT Population (observed), which consisted of participants in the mITT Population excluding participants who had no HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). 99999 indicates data was not collected for Week 96 analysis; as the study was terminated early. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).	
End point type	Secondary
End point timeframe: Weeks 48 and 96	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[14]	52 ^[15]	51 ^[16]	53 ^[17]
Units: Participants				
Week 48; n=40, 42, 40, 43 Week 96; n=0, 0, 0, 0	38 99999	42 99999	40 99999	40 99999

Notes:

[14] - mITT Population (observed)

[15] - mITT Population (observed)

[16] - mITT Population (observed)

[17] - mITT Population (observed)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with newly emergent genotypic resistance using all on-treatment isolates

End point title	Number of participants with newly emergent genotypic resistance using all on-treatment isolates
-----------------	-------------------------------------------------------------------------------------------------

End point description:

The emergence of genotypic resistance among samples selected for drug resistance testing were assessed by searching for all reverse transcriptase substitutions and protease inhibitor substitutions listed in the International Acquired Immunodeficiency Syndrome (AIDS) Society-United States of America (IAS-USA) list of HIV-1 drug resistance mutations. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early. The emergence of genotypic resistance is presented for participants in the mITT Population who had Baseline and on-treatment genotypic resistance testing and who had successful sequencing.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 24 weeks

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5 ^[18]	5 ^[19]	2 ^[20]	1 ^[21]
Units: Participants				
Protease inhibitor substitution	1	0	0	0
Reverse transcriptase substitution	3	5	2	0

Notes:

[18] - mITT Population

[19] - mITT Population

[20] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with newly emergent phenotypic resistance using all on-treatment isolates

End point title	Number of participants with newly emergent phenotypic resistance using all on-treatment isolates
-----------------	--------------------------------------------------------------------------------------------------

End point description:

Phenotypic resistance to a drug is defined as a fold change (i.e., ratio of the 50% inhibitory concentration (IC₅₀) of the clinical isolate to the IC₅₀ of the reference strain) which is greater than the cut-off for reduced susceptibility. Emergent phenotypic resistance to BMS-955176/GSK3532795 was defined as a Baseline fold change IC₅₀ ≤ 3 and an on-treatment fold change IC₅₀ > 3. The number of participants with newly emergent phenotypic resistance is presented for participants in the mITT Population who had Baseline and on-treatment phenotypic resistance testing. The outcome was originally designed to be assessed up to 96 weeks of treatment, but it was analyzed up to Week 24 as the study was terminated early.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 24 weeks

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[22]	3 ^[23]	0 ^[24]	1 ^[25]
Units: Participants	1	0		0

Notes:

[22] - mITT Population

[23] - mITT Population

[24] - mITT Population

[25] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in logarithm to the base 10 (log₁₀) HIV-1 RNA over time

End point title	Change from Baseline in logarithm to the base 10 (log ₁₀) HIV-1 RNA over time
-----------------	-------------------------------------------------------------------------------------------

End point description:

Blood samples were collected for analysis of HIV-1 RNA. Values obtained at Day 1 were considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Change from Baseline in plasma HIV-1 RNA (log₁₀) is summarized over time for the mITT Population using observed values, which excluded participants without HIV-1 RNA result data in the

assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). 99999 indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[26]	52 ^[27]	51 ^[28]	53 ^[29]
Units: Log 10 c/mL				
arithmetic mean (standard deviation)				
Week 2, n=8, 6, 10, 8	-1.927 (± 0.3726)	-1.930 (± 0.4785)	-2.006 (± 0.3783)	-2.003 (± 0.3662)
Week 4, n=50, 51, 51, 50	-2.083 (± 0.5870)	-2.082 (± 0.5480)	-2.142 (± 0.5092)	-2.305 (± 0.4554)
Week 8, n=49, 51, 49, 48	-2.308 (± 0.6989)	-2.262 (± 0.7152)	-2.334 (± 0.6046)	-2.516 (± 0.6408)
Week 12, n=49, 50, 47, 47	-2.372 (± 0.8215)	-2.351 (± 0.7622)	-2.441 (± 0.6372)	-2.730 (± 0.6254)
Week 16, n=47, 50, 46, 46	-2.502 (± 0.8650)	-2.432 (± 0.7991)	-2.513 (± 0.6429)	-2.862 (± 0.6903)
Week 24, n=46, 47, 45, 44	-2.506 (± 0.8094)	-2.557 (± 0.7956)	-2.505 (± 0.7284)	-2.919 (± 0.7584)
Week 32, n=44, 42, 42, 44	-2.497 (± 0.8045)	-2.642 (± 0.7408)	-2.528 (± 0.7392)	-2.920 (± 0.7488)
Week 40, n=40, 42, 41, 43	-2.605 (± 0.7096)	-2.640 (± 0.7391)	-2.581 (± 0.6803)	-2.949 (± 0.7665)
Week 48, n=40, 42, 40, 43	-2.650 (± 0.6824)	-2.649 (± 0.7388)	-2.557 (± 0.6711)	-2.935 (± 0.7415)
Week 60; n=22, 24, 19, 20	-2.705 (± 0.6379)	-2.810 (± 0.5765)	-2.703 (± 0.7455)	-2.906 (± 0.5646)
Week 72; n=5, 5, 5, 6	-2.586 (± 0.4682)	-2.733 (± 0.6809)	-2.725 (± 0.5025)	-2.780 (± 0.6598)
Week 84; n= 2, 1, 2, 2	-0.993 (± 3.4142)	-3.032 (± 99999)	-3.155 (± 0.1218)	-3.257 (± 0.5700)

Notes:

[26] - mITT Population (observed)

[27] - mITT Population (observed)

[28] - mITT Population (observed)

[29] - mITT Population (observed)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in cluster of differentiation (CD)4+ thymus (T)-cell counts over time

End point title	Change from Baseline in cluster of differentiation (CD)4+ thymus (T)-cell counts over time
-----------------	--------------------------------------------------------------------------------------------

End point description:

CD4+ T-cell counts was assessed using flow cytometry. Values obtained at Day 1 were considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Change from Baseline in CD4+T- cell counts is summarized over time for the mITT Population using observed values, which excluded participants without HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). 99999 indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[30]	52 ^[31]	51 ^[32]	53 ^[33]
Units: Cells per microliter				
arithmetic mean (standard deviation)				
Week 4, n=50, 51, 50, 50	41.6 (± 148.92)	72.9 (± 167.53)	52.9 (± 149.54)	64.7 (± 145.51)
Week 8, n=48, 49, 49, 47	59.1 (± 219.64)	81.8 (± 126.79)	88.4 (± 177.68)	117.4 (± 230.74)
Week 12, n=49, 49, 47, 47	110.4 (± 170.87)	120.0 (± 178.04)	129.7 (± 175.73)	142.5 (± 118.39)
Week 16, n=46, 50, 46, 46	90.8 (± 200.76)	99.7 (± 171.16)	128.0 (± 212.09)	140.5 (± 179.70)
Week 24, n=46, 46, 44, 44	94.3 (± 175.00)	81.2 (± 195.39)	92.5 (± 144.04)	134.7 (± 151.70)
Week 32, n=44, 42, 42, 44	131.5 (± 207.69)	103.5 (± 172.15)	99.7 (± 171.95)	175.6 (± 152.48)
Week 40, n=41, 42, 41, 43	175.9 (± 235.99)	194.4 (± 235.14)	167.3 (± 215.23)	222.5 (± 191.99)
Week 48, n=40, 41, 39, 43	158.3 (± 228.90)	152.0 (± 204.56)	161.4 (± 221.65)	232.4 (± 207.71)
Week 60; n=22, 23, 19, 20	168.4 (± 148.63)	156.5 (± 301.91)	198.3 (± 137.51)	204.7 (± 154.86)
Week 72; n=5, 5, 5, 7	176.2 (± 98.50)	336.8 (± 329.32)	240.4 (± 240.48)	209.7 (± 97.79)
Week 84; n=2, 1, 2, 2	-4.0 (± 173.95)	203.0 (± 99999)	97.0 (± 285.67)	165.5 (± 70.00)

Notes:

[30] - mITT Population (observed)

[31] - mITT Population (observed)

[32] - mITT Population (observed)

[33] - mITT Population (observed)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the percentage of CD4+ T-cells over time

End point title	Change from Baseline in the percentage of CD4+ T-cells over
-----------------	-------------------------------------------------------------

End point description:

CD4+ T-cell counts overall was assessed using flow cytometry. Values obtained at Day 1 were considered as Baseline value. Change from Baseline was calculated as value at indicated time point minus Baseline value. Change from Baseline in percentage of CD4+T- cell counts is summarized over time for the mITT Population using observed values, which excluded participants without HIV-1 RNA result data in the assessment visit windows due to discontinuation and who discontinued on or after the date of site notification of study termination by the sponsor (10 October 2016). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). 99999 indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72 and 84

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[34]	52 ^[35]	51 ^[36]	53 ^[37]
Units: Percentage of CD4+T- cells				
arithmetic mean (standard deviation)				
Week 4, n=50, 51, 50, 50	4.56 (± 3.195)	3.43 (± 3.982)	3.93 (± 3.210)	3.87 (± 4.284)
Week 8, n=48, 49, 49, 47	5.02 (± 4.650)	4.15 (± 4.047)	5.15 (± 3.943)	5.09 (± 4.257)
Week 12, n=49, 49, 47, 47	5.47 (± 4.570)	5.39 (± 4.577)	6.22 (± 4.450)	6.29 (± 4.557)
Week 16, n=46, 50, 46, 46	6.20 (± 6.163)	5.65 (± 4.179)	6.95 (± 4.019)	6.87 (± 4.763)
Week 24, n=46, 46, 44, 44	7.68 (± 5.834)	5.71 (± 4.542)	6.96 (± 4.761)	5.94 (± 5.730)
Week 32, n=44, 42, 42, 44	7.75 (± 6.559)	7.36 (± 5.457)	6.90 (± 6.498)	8.37 (± 6.253)
Week 40, n=41, 42, 41, 43	7.90 (± 6.612)	6.97 (± 8.253)	7.94 (± 5.601)	9.06 (± 5.538)
Week 48, n=40, 41, 39, 43	9.07 (± 6.311)	7.62 (± 6.218)	9.59 (± 4.828)	10.16 (± 6.262)
Week 60; n=22, 23, 19, 20	9.41 (± 6.290)	8.44 (± 7.788)	11.36 (± 6.568)	10.73 (± 7.098)
Week 72; n=5, 5, 5, 7	8.56 (± 3.436)	9.92 (± 4.147)	12.46 (± 9.557)	9.67 (± 3.982)
Week 84; n=2, 1, 2, 2	-0.75 (± 8.839)	4.60 (± 99999)	19.50 (± 11.314)	12.90 (± 4.950)

Notes:

[34] - mITT Population (observed)

[35] - mITT Population (observed)

[36] - mITT Population (observed)

[37] - mITT Population (observed)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with serious adverse events (SAEs) and adverse events leading to discontinuation (AELD)

End point title	Number of participants with serious adverse events (SAEs) and adverse events leading to discontinuation (AELD)
-----------------	----------------------------------------------------------------------------------------------------------------

End point description:

Any untoward medical occurrence that at any dose: results in death, is life threatening, requires

inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE. Number of participants with SAEs and AELDs is summarized.

End point type	Secondary
End point timeframe:	
Up to Week 96	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[38]	52 ^[39]	51 ^[40]	53 ^[41]
Units: Participants				
SAEs	3	5	2	5
AELD	1	4	5	10

Notes:

[38] - mITT Population

[39] - mITT Population

[40] - mITT Population

[41] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with at least one Centers for Disease Control (CDC) class C event

End point title	Number of participants with at least one Centers for Disease Control (CDC) class C event
End point description:	
The occurrence of new AIDS defining events, that is CDC class C events is presented.	
End point type	Secondary
End point timeframe:	
Up to Week 96	

End point values	BMS-955176/GSK35 32795 60 mg + TDF/FTC	BMS-955176/GSK35 32795 120 mg + TDF/FTC	BMS-955176/GSK35 32795 180 mg + TDF/FTC	EFV 600 mg + TDF/FTC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50 ^[42]	52 ^[43]	51 ^[44]	53 ^[45]
Units: Participants	0	2	0	0

Notes:

[42] - mITT Population

[43] - mITT Population

[44] - mITT Population

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed plasma concentration (C_{max}), observed pre-dose plasma concentration (C₀) and observed plasma concentration at the end of a dosing interval (C_{tau}) of BMS-955176/GSK3532795

End point title	Maximum observed plasma concentration (C _{max}), observed pre-dose plasma concentration (C ₀) and observed plasma concentration at the end of a dosing interval (C _{tau}) of BMS-955176/GSK3532795 ^[46]
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Serial blood samples were collected at indicated time points for intensive pharmacokinetic (PK) assessment. The PK assessments were performed on evaluable PK Population, a sub-population which included all treated participants who had adequate PK profiles.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 (evening pre-dose) and 24 hours (morning pre-dose) at Week 2 (Days 12 to 16)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8 ^[47]	6 ^[48]	10 ^[49]	
Units: Nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
C _{max}	1945.342 (± 16.0)	3162.161 (± 28.8)	4645.266 (± 16.2)	
C ₀	1065.102 (± 25.2)	1800.952 (± 33.4)	2728.671 (± 17.8)	
C _{tau}	1100.138 (± 15.1)	1656.578 (± 39.7)	2705.751 (± 26.8)	

Notes:

[47] - Evaluable PK Population

[48] - Evaluable PK Population

[49] - Evaluable PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time of maximum observed plasma concentration (T_{max}) of BMS-

955176/GSK3532795

End point title	Time of maximum observed plasma concentration (Tmax) of BMS-955176/GSK3532795 ^[50]
-----------------	-----------------------------------------------------------------------------------------------

End point description:

Serial blood samples were collected at indicated time points for intensive PK assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (morning) and 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 (evening pre-dose) and 24 hours (morning pre-dose) at Week 2 (Days 12 to 16)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8 ^[51]	6 ^[52]	10 ^[53]	
Units: Hour				
median (full range (min-max))	4.00 (1.6 to 8.2)	4.29 (4.0 to 5.1)	5.50 (1.0 to 12.0)	

Notes:

[51] - Evaluable PK Population

[52] - Evaluable PK Population

[53] - Evaluable PK Population

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the concentration-time curve in one dosing interval (AUC [tau]) of BMS-955176/GSK3532795

End point title	Area under the concentration-time curve in one dosing interval (AUC [tau]) of BMS-955176/GSK3532795 ^[54]
-----------------	---------------------------------------------------------------------------------------------------------------------

End point description:

Serial blood samples were collected at indicated time points for intensive PK assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (morning) and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 12 (evening pre-dose) and 24 hours (morning pre-dose) at Week 2 (Days 12 to 16)

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period.

End point values	BMS- 955176/GSK35 32795 60 mg + TDF/FTC	BMS- 955176/GSK35 32795 120 mg + TDF/FTC	BMS- 955176/GSK35 32795 180 mg + TDF/FTC	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8 ^[55]	6 ^[56]	10 ^[57]	
Units: Hour*nanograms per milliliter				
geometric mean (geometric coefficient of variation)	34226.751 (± 18.73)	55251.956 (± 32.88)	87128.359 (± 20.79)	

Notes:

[55] - Evaluable PK Population

[56] - Evaluable PK Population

[57] - Evaluable PK Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Non-serious adverse events and serious adverse events (SAEs) were collected from the start of study treatment until Week 96.

Adverse event reporting additional description:

Non-SAEs and SAEs were collected in the mITT Population, which comprised of all participants who received at least one dose of BMS-955176/GSK3532795 or EFV.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	BMS-955176/GSK3532795 60 mg + TDF/FTC
-----------------------	---------------------------------------

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 milligrams (mg) active dose, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing efavirenz (EFV) placebo matching 600 mg from Day 1 to Week 48.

Reporting group title	BMS-955176/GSK3532795 120 mg + TDF/FTC
-----------------------	----------------------------------------

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 120 mg active dose, BMS-955176/GSK3532795 placebo matching 60 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.

Reporting group title	BMS-955176/GSK3532795 180 mg + TDF/FTC
-----------------------	----------------------------------------

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 60 mg active dose, BMS-955176/GSK3532795 120 mg active dose and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV placebo matching 600 mg from Day 1 to Week 48.

Reporting group title	EFV 600 mg + TDF/FTC
-----------------------	----------------------

Reporting group description:

In the morning, with a meal, participants took one pill once daily from each of the three blinded bottles provided to them, containing BMS-955176/GSK3532795 placebo matching 60 mg, BMS-955176/GSK3532795 placebo matching 120 mg and open-label TDF/FTC 300/200 mg from Day 1 to Week 48. At bed time, on an empty stomach, without food, participants took one pill once daily from the bottle containing EFV 600 mg active dose from Day 1 to Week 48.

Serious adverse events	BMS-955176/GSK3532795 60 mg + TDF/FTC	BMS-955176/GSK3532795 120 mg + TDF/FTC	BMS-955176/GSK3532795 180 mg + TDF/FTC
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 50 (6.00%)	5 / 52 (9.62%)	2 / 51 (3.92%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			

Investigations			
HEPATIC ENZYME INCREASED			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
OVERDOSE			
subjects affected / exposed	0 / 50 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal injury			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
VENTRICULAR EXTRASYSTOLES			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Orthostatic intolerance			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 50 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLITIS ULCERATIVE			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TOOTHACHE			

subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
PNEUMOTHORAX SPONTANEOUS			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteonecrosis			
subjects affected / exposed	0 / 50 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
INTERVERTEBRAL DISCITIS			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 50 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus infection			

subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic infection			
subjects affected / exposed	0 / 50 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	EFV 600 mg + TDF/FTC		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 53 (9.43%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Investigations			
HEPATIC ENZYME INCREASED			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
OVERDOSE			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal injury			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
VENTRICULAR EXTRASYSTOLES			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Orthostatic intolerance			

subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COLITIS ULCERATIVE			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TOOTHACHE			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
PNEUMOTHORAX SPONTANEOUS			
alternative dictionary used: MedDRA 19.0			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteonecrosis			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			

INTERVERTEBRAL DISCITIS			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metapneumovirus infection			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic infection			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	BMS- 955176/GSK353279 5 60 mg + TDF/FTC	BMS- 955176/GSK353279 5 120 mg + TDF/FTC	BMS- 955176/GSK353279 5 180 mg + TDF/FTC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 50 (82.00%)	46 / 52 (88.46%)	45 / 51 (88.24%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	0 / 50 (0.00%)	3 / 52 (5.77%)	0 / 51 (0.00%)
occurrences (all)	0	3	0
Nervous system disorders			
Dizziness			

subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	2 / 52 (3.85%) 2	2 / 51 (3.92%) 2
Headache subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	6 / 52 (11.54%) 8	7 / 51 (13.73%) 8
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	1 / 52 (1.92%) 1	3 / 51 (5.88%) 3
Pyrexia subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	0 / 52 (0.00%) 0	4 / 51 (7.84%) 4
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	20 / 50 (40.00%) 30	22 / 52 (42.31%) 33	31 / 51 (60.78%) 58
Nausea subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 4	4 / 52 (7.69%) 4	6 / 51 (11.76%) 7
Abdominal pain subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 6	6 / 52 (11.54%) 8	10 / 51 (19.61%) 14
Vomiting subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	5 / 52 (9.62%) 6	3 / 51 (5.88%) 4
Abdominal pain upper subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 4	3 / 52 (5.77%) 5	4 / 51 (7.84%) 5
Dyspepsia subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	5 / 52 (9.62%) 6	2 / 51 (3.92%) 2
Abdominal distension			

subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 52 (0.00%) 0	3 / 51 (5.88%) 3
Irritable bowel syndrome subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 52 (1.92%) 1	3 / 51 (5.88%) 3
Toothache subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Reproductive system and breast disorders Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 52 (0.00%) 0	3 / 51 (5.88%) 3
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	1 / 52 (1.92%) 1	1 / 51 (1.96%) 1
Cough subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	3 / 52 (5.77%) 3	1 / 51 (1.96%) 1
Skin and subcutaneous tissue disorders Dermatitis allergic subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Drug eruption subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 52 (0.00%) 0	1 / 51 (1.96%) 1
Pruritus subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 3	1 / 52 (1.92%) 1	7 / 51 (13.73%) 9
Abnormal dreams subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	4 / 52 (7.69%) 5	1 / 51 (1.96%) 1

Anxiety subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 52 (1.92%) 1	1 / 51 (1.96%) 1
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	1 / 52 (1.92%) 1	3 / 51 (5.88%) 3
Muscle spasms subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	1 / 52 (1.92%) 1	3 / 51 (5.88%) 3
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	5 / 50 (10.00%) 8	4 / 52 (7.69%) 5	6 / 51 (11.76%) 8
Pharyngitis subjects affected / exposed occurrences (all)	6 / 50 (12.00%) 7	3 / 52 (5.77%) 4	2 / 51 (3.92%) 4
Upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 7	8 / 52 (15.38%) 11	6 / 51 (11.76%) 8
Influenza subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	6 / 52 (11.54%) 6	1 / 51 (1.96%) 1
Bronchitis subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	4 / 52 (7.69%) 5	0 / 51 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 5	1 / 52 (1.92%) 1	1 / 51 (1.96%) 1
Conjunctivitis subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	0 / 52 (0.00%) 0	1 / 51 (1.96%) 1
Urethritis subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 5	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0

Non-serious adverse events	EFV 600 mg + TDF/FTC		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	48 / 53 (90.57%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		
Nervous system disorders			
Dizziness			
subjects affected / exposed	21 / 53 (39.62%)		
occurrences (all)	27		
Headache			
subjects affected / exposed	6 / 53 (11.32%)		
occurrences (all)	8		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 53 (3.77%)		
occurrences (all)	2		
Pyrexia			
subjects affected / exposed	2 / 53 (3.77%)		
occurrences (all)	2		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	4 / 53 (7.55%)		
occurrences (all)	4		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	8 / 53 (15.09%)		
occurrences (all)	9		
Nausea			
subjects affected / exposed	7 / 53 (13.21%)		
occurrences (all)	8		
Abdominal pain			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		
Vomiting			

subjects affected / exposed	2 / 53 (3.77%)		
occurrences (all)	2		
Abdominal pain upper			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Irritable bowel syndrome			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Reproductive system and breast disorders			
Erectile dysfunction			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Cough			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Drug eruption			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Pruritus			

subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	3		
Abnormal dreams			
subjects affected / exposed	6 / 53 (11.32%)		
occurrences (all)	6		
Anxiety			
subjects affected / exposed	4 / 53 (7.55%)		
occurrences (all)	4		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		
Muscle spasms			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 53 (7.55%)		
occurrences (all)	4		
Pharyngitis			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	4		
Upper respiratory tract infection			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	2		
Influenza			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences (all)	4		
Bronchitis			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		
Sinusitis			

subjects affected / exposed	1 / 53 (1.89%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	2 / 53 (3.77%)		
occurrences (all)	2		
Urethritis			
subjects affected / exposed	0 / 53 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 April 2015	This amendment served to clarify inclusion/exclusion criteria, clarify virologic failure, clarify resistance testing, correct Sparse PK sample collection time, provide additional details on dosage forms, and modify references to discontinuation due to pregnancy to ensure consistency.
22 May 2015	This amendment served to clearly define most contraception methods, incorporate a post-dosing safety follow-up visit, require women of childbearing potential (WOCBP) to follow study instructions, add a time to loss of virologic response (TLOVR) analysis and define virologic rebound, add information on laboratory assessments, update the division of AIDS (DAIDS) toxicity table as appendices, and clarify that AIDS history will be taken at screening.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported